June 20, 2025 — Influx Healthtech Ltd, a rapidly growing Contract Development and Manufacturing Organization (CDMO), is making waves in the Indian wellness and healthcare sector with its upcoming IPO listing on the NSE Emerge platform. The company, known for its diversified operations in Nutraceuticals, Cosmetics, Ayurveda, Veterinary Feed Supplements, and Home Care Products, is now entering a new phase of strategic growth and public participation.

Influx Healthtech Ltd. IPO Details at a Glance

• IPO Dates: June 18, 2025 to June 20, 2025
• Face Value: ₹10 per share
• Issue Price: ₹96 per share
• Lot Size: 1,200 shares
• Total Issue Size (Excluding Market Maker): 57,94,800 shares (₹55.63 Cr)
• Fresh Issue (Ex Market Maker): 46,94,400 shares (₹45.07 Cr)
• Offer for Sale: 11,00,400 shares (₹10.56 Cr)
• Issue Type: Bookbuilding IPO
• Listing Platform: NSE SME

Who is Influx Healthtech Ltd?

Influx Healthtech Ltd is a new-age CDMO player that has cemented its position as a trusted manufacturing partner across multiple sectors, including:

• Nutraceuticals: Wellness supplements and functional health products
• Cosmetics: Clean, effective formulations for skincare and beauty
• Ayurveda: Traditional Indian therapeutic formulations
• Veterinary Feed: Quality supplements for animal health and nutrition
• Home Care: Safe and sustainable household products

This cross-sector diversification, combined with deep R&D expertise and a zero-debt track record, has given the company a resilient foundation in India’s booming wellness market.

Investor Confidence Soars

Investor interest has skyrocketed, with the IPO witnessing 187.31 times subscription, reflecting strong market confidence in the company’s fundamentals, leadership, and vision. This overwhelming response underscores Influx Healthtech’s credibility, operational stability, and growth potential.

Utilization of IPO Proceeds

The funds raised through the fresh issue will primarily be directed towards:

• Setting up new state-of-the-art manufacturing units
• Purchasing advanced machinery to boost production capacity by approx 2.5 to 3 times
• Expanding R&D capabilities to enter into specialised human and veterinary nutrition

With this investment, the company aims to scale its output to meet rising domestic and international demand.

Future Plans: From India to the World

Influx Healthtech’s leadership is sharply focused on tapping global markets. With rising global awareness about natural, science-backed wellness and the shift towards clean-label and plant-based products, the company plans to:

• Venture Into Specialty Nutrition Segments
• Expand Exports to strategic international markets
• Establish itself as a globally competitive Indian CDMO brand

Debt-Free Growth and Strong Financial Discipline

One of the most remarkable aspects of Influx Healthtech’s journey is that the company has been entirely loan-free since its inception. It has funded its growth purely through internal accruals and operational profits — a rare feat in an industry that often depends on leverage. This speaks volumes about the company's fiscal prudence and sustainable business model.

Why Influx Healthtech Is a Strong Bet for Investors

• High Subscription Demand: 200x+ subscription shows strong institutional and retail confidence
• Robust Sector: Wellness, healthcare, and nutrition are high-growth industries in India
• Debt-Free Operations: Indicates financial health and risk resilience
• Clear Roadmap: Well-defined post-IPO utilization strategy and growth plan
• Multi-Sector Presence: Reduces dependency on a single market vertical
• Global Expansion Vision: Strong potential to tap into export and specialty nutrition markets

Final Word

Influx Healthtech Ltd is more than just a CDMO—it is a symbol of modern, innovation-led Indian manufacturing excellence. As it enters the public market through the NSE Emerge platform, it offers a promising opportunity for investors looking to be part of India’s wellness revolution. With a clear vision, zero debt, and unmatched growth potential, Influx Healthtech Ltd could well be one of the most rewarding investment stories of 2025.